Clinical Trials Directory

Trials / Unknown

UnknownNCT03428191

Target Effect-site Concentration of Remifentanil in Transperineal Prostate Puncture

The Research About the Target Effect-site Concentration of Remifentanil Inhibiting Stress Reaction of the Perineal Prostate Puncture When Dexmedetomidine Being Continuous Pumping

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Chinese Medical Association · Network
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The research about the target effect-site concentration of remifentanil, inhibiting stress reaction of the perineal prostate puncture when Dexmedetomidine being continuous pumping

Detailed description

Patients who were scheduled to undergo transperineal prostate puncture and biopsy were recruited into our study. In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method. The first target effect-site concentration of remifentanil was set to 4.5ng/ml, the difference of adjacent target concentration was 0.5 ng/ml. Cardiovascular positive reaction was defined as the changes of heart rate or systolic blood pressure was more than 15% compared with baseline values, or body movement observed. The adjacent target concentration difference was adjusted to 0.2 ng/ml after 3 negative and positive reaction cycles. If the first had a cardiovascular positive reaction, the target concentration of remifentanil increased by a concentration gradient. Conversely, the target concentration of remifentanil decreased by a concentration gradient.

Conditions

Interventions

TypeNameDescription
DRUGRemifentanyl+DexmedetomidineIn all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.

Timeline

Start date
2017-01-01
Primary completion
2018-02-01
Completion
2018-02-01
First posted
2018-02-09
Last updated
2018-02-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03428191. Inclusion in this directory is not an endorsement.